Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer

Published:2011-05-11 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Shang Pan Feng¹,Kwong Joey²,Wang Zhi Ping³,Tian Jinhui⁴,Jiang Lei⁴,Yang KeHu⁴,Yue Zhong Jin¹,Tian Jun Qiang⁴

Affiliation:

1. Second Hospital of Lanzhou University; Department of Urology; No. 82, Cui Ying Men Street Lanzhou City Gansu China 730030

2. London School of Hygiene & Tropical Medicine; Department of Non-Communicable Disease Epidemiology; Keppel Street London UK WC1E 7HT

3. Second Hospital of Lanzhou University; Institute of Urology; No. 82, Cui Ying Men Street Lanzhou City Gansu China 730030

4. Lanzhou University; Evidence-Based Medicine Center, School of Basic Medical Sciences; No. 199, Donggang West Road Lanzhou City Gansu China 730000

Publisher

Wiley

Subject

Pharmacology (medical)

Reference172 articles.

1. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer;Cheng;International Journal of Urology,2005

2. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer;Melekos;Cancer,1993

3. BCG versus epirubicin in the prophylaxis of multiple superficial bladder tumours: results of a prospect;Melekos;International Urology and Nephrology,1996

4. Intravesical bacillus Calmette-Guérin versus epirubicin in the prophylaxis of recurrent and/or multiple superficial bladder tumours;Melekos;Oncology,1996

5. Long-term efficacy results of EORTC Genito-Urinary Group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, Bacillus Calmette-Guérin, and Bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder;Sylvester;European Urology,2010

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse drug reactions of intravesical instillation therapy for bladder cancer: based on FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-08-22

2. Use of Bladder-Related Medication in Non-Muscle Invasive Bladder Cancer Patients;Cancers;2024-05-20

3. Comparing Clinical Efficacy of Different Bacillus Calmette-Guérin Strains in Patients With T1 High Grade Bladder Cancer;Anticancer Research;2024-02-29

4. The Evolving Role of PD-(L)1 Inhibition in Optimizing Outcomes for High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC): A Podcast;Advances in Therapy;2024-02-02

5. Comparative analysis of recurrence rates between intravesical gemcitabine and bacillus Calmette–Guérin induction therapy following transurethral resection of bladder tumors in patients with intermediate- and high-risk bladder cancer: A retrospective multicenter study;Investigative and Clinical Urology;2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3